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Abstract 
Background: Factors affecting kidney function and proteinuria among HIV+ and HIV- 
persons need better characterization. 
Methods: We evaluated estimated glomerular filtration rate (eGFR, mL/min per 1.73 m2) 
changes, proteinuria prevalence (a urine protein-to-creatinine ratio [UPCr] of >0.2 at two 
consecutive visits) and associated factors among HIV+ and HIV- men.  
Results: There were 917 HIV+ men receiving HAART, 159 HIV+ men not receiving 
HAART, and 1305 HIV- men seen from 10/2003 to 9/2014. Median annual eGFR change 
was -0.5%,  -0.8% for HIV+ and -0.3% for HIV- men (p<0.001). Factors significantly 
(p<0.05) associated with >3% annual eGFR decline were: HAART receipt (but no 
specific ART drug), age>50, hypertension, diabetes, current smoking. Proteinuria existed 
in 14.9% of visit-pairs among HAART recipients, 5.8% among non-HAART recipients, 
and 1.9% among HIV- men, and was associated with subsequent annual >3% eGFR 
decline (OR 1.80, p<0.001). Proteinuria-associated factors also included HAART use (vs. 
HIV-), age >50 (vs. <40), diabetes, hypertension, current smoking, HCV-infection (all 
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p<0.05) and, among HIV+ men, lower CD4 cell count, didanosine, saquinavir, or 
nelfinavir use (all p<0.05). After adjusting for proteinuria, among HAART users, having 
a detectable HIV RNA, cumulative use of tenofovir disoproxil fumarate (TDF), 
emtricitabine, ritonavir, atazanavir, any protease inhibitor, or fluconazole were associated 
with >3% annual eGFR decline. 
Conclusions: Longitudinal kidney function decline was associated with HAART use but 
no individual ART drug, and traditional kidney disease risks.  Proteinuria was nearly 7 
times more common in HAART-treated men than HIV- men, reflected recent eGFR 
decline and predicted subsequent eGFR decline.  
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Background  
Kidney disease is an important cause of morbidity among HIV+ persons[1-4]. While HIV 
itself is a known kidney pathogen[5] and accounted for much kidney disease among HIV+ 
persons before the advent of highly active antiretroviral therapy (HAART)[6], it is now 
clear that diverse multifactorial processes that can  impacting kidney function in 
HAART-treated HIV+ persons[7-10]. Nuanced longitudinal characterization of kidney 
function over time and of factors impacting it among HIV+ persons receiving HAART is 
needed. Using an appropriate control group of HIV- but at-risk persons allows 
differentiation of HIV-specific risk factors from those that are not unique to HIV+ 
individuals, such as hypertension and diabetes mellitus. Likewise, the role of systemic 
inflammation in kidney disease development, particularly among HIV+ persons, requires 
better evaluation[11-15].  These all are important to evaluate among HAART-treated 
virally-suppressed HIV+ persons, for whom survival has been extended and in whom 
chronic co-morbidities, aging, antiretroviral therapies, and systemic inflammation may 
contribute to the development and progression of kidney disease[16-18]. 
     Glomerular filtration rate estimates (eGFR) and urine protein-to-creatinine ratios 
(UPCR) are complementary indicators of kidney function and damage widely used for 
kidney disease screening and monitoring in the general population[19]. While GFR 
estimates are standard monitoring tools in the management of HIV+ persons, quantitative 
assessments of proteinuria are less common, and concurrent examination of both are 
uncommon in this population. 
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     In this report, we assessed factors impacting longitudinal kidney function and 
proteinuria among HIV+ and demographically similar HIV- men followed in the 
Multicenter AIDS Cohort Study (MACS).  
Methods 
The Cohort 
The MACS[20] is an ongoing multi-center, prospective study of men who have sex with 
men (MSM). MACS sites in Baltimore, MD-Washington, DC; Chicago, IL; Los Angeles, 
CA; and Pittsburgh, PA have enrolled a total of 6,972 men in 1984-85, 1987-90, and 
2001-03. The MACS prospectively schedules participants for semi-annual study visits 
where medical and therapy histories, physical and behavioral assessments, and biological 
specimens are collected under standardized protocols.  Individuals eligible for the current 
study were HIV+ and HIV-participants who contributed at least three serum creatinine 
(SCr) measurements from visit 40 (2003), when SCr was first measured in the study, 
through visit 61 (2014).   
Hepatitis B virus (HBV) co-infection was determined by the presence of a positive 
hepatitis B surface antigen. Hepatitis C virus (HCV) co-infection was defined by a 
positive HCV RNA.  HAART was defined in accordance with US Department of Health 
and Human Services (DHHS) treatment guidelines (www.aidsinfo.gov; November 2014 
version) as use of three or more antiretroviral (ART) drugs including one or more of 
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protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), a non-
nucleoside reverse transcriptase inhibitor (NNRTI), integrase inhibitor, or entry inhibitor 
(including fusion inhibitors). Information regarding the presence of traditional risk 
factors for CKD (eg hypertension, diabetes) were based on a combination of: 1) 
participant self-report; 2) study-obtained measurements; 3) medication usage.   
     Informed consent from each participant and approval from each local institutional 
review board were obtained. 
Outcomes and Analytic Methods 
The baseline visit was defined as the first visit with SCr data. Participants with 
incident HIV infection (n=93) or those HIV+ men who initiated HAART during the study 
period (n=124) were included as HIV- before HIV infection and HIV+ but not receiving 
HAART before HAART initiation, respectively. GFR was estimated in mL/min/1.73 m2 
using the serum creatinine-based CKD-EPI equation[21]. Baseline characteristics of HIV- 
and HIV+ subject groups were compared using the Wilcoxon test or the Chi-square test, 
when appropriate. Cochran-Armitage Trend Test was used to examine trends in the 
prevalence of hypertension, diabetes mellitus, and current smoking by baseline eGFR 
strata (≥90, 60-89 and <60).  
We first evaluated longitudinal eGFR changes over an 11-year study period.  For 
each person, a simple linear regression of their log-transformed eGFR with years of 
follow-up from baseline as a predictor was conducted. After examining the linear trend of 
eGFR over time, the annual eGFR percent change was calculated using this formula: 
(exp(log gfrslp)-1)*100%, where log gfrslp was the estimate of change in log-
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transformed eGFR per year obtained from the linear regression. Individuals were then 
classified according to whether the annual eGFR declined by >3%. Multivariable logistic 
regression models were constructed to evaluate the association of potential risk factors 
with the odds of annual eGFR decline >3%. Potential risk factors examined were baseline 
characteristics: HIV/HAART status (3 groups: HIV- [reference], HIV+ no-HAART, 
HIV+ HAART), eGFR categories (<60, 60-89, ≥90 [reference]), age (<40 [reference], 
40-49, 50-59, ≥60), race (White [reference], African-American, and Hispanic or other
race), a history of diabetes, a history of hypertension, cigarette smoking status (current, 
former, never [reference]), HBV and/or HCV infection. Cohort entry status (pre-2001 
[reference] vs. 2001-03 cohort) was included to control for additional differences in the 
cohorts, and the number of eGFR measurements contributed per person. Among HIV+ 
men, a history of a clinical AIDS diagnosis, baseline CD4+ T-cell counts (≤200, 201-350, 
351-500, and >500 cells/mm3[reference]) and detectable plasma HIV RNA (≥50
copies/mL) levels were also evaluated in association with eGFR decline. Among HIV+ 
HAART-users, years from HAART initiation to baseline and cumulative years on 
individual antiretroviral drugs from HAART initiation to baseline were also examined in 
separate models.  Baseline eGFR levels and age were fixed in the final model; other 
factors with a p-value <0.1 were kept in the final multivariable model. 
We then measured the prevalence of confirmed proteinuria, defined as a UPCR  
>0.2 at two consecutive visits (no more than 1 year apart), and evaluated factors
associated with confirmed proteinuria among HIV+ and HIV- participants from April 
2006 (when UPCR measurements were added to the protocol) through September 2014. 
This definition of proteinuria was used in order to minimize the likelihood that the 
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presence of proteinuria was due to a transient process not related to chronic kidney 
disease. Multivariable logistic regression models were used to determine factors 
associated with proteinuria. In this analysis, except for HIV/HAART status and baseline 
eGFR, other exposure variables were time-varying and included those taken from the 
visit (V(i-1)) prior to the first visit of the visit-pairs at which proteinuria was assessed.  
Potential risk factors considered in these models included those present in the eGFR 
analyses, as well as the presence of annual eGFR decline >3% from baseline to V(i). 
Separate models were constructed for HAART-users when examining specific 
antiretroviral drugs. Generalized estimating equations (GEE) were used to analyze 
longitudinal data with repeated measures. 
 We also examined whether proteinuria predicted eGFR change. The key exposure 
variable here was proteinuria, and the outcome variable was annual eGFR decline >3% in 
the next year (i.e., the calculation was based on three eGFRs: GFR at the current visit 
[V(i) when proteinuria was determined] and the two visits that followed). Other exposure 
variables adjusted in multivariable logistic regression models were similar to the previous 
analysis of proteinuria, but were taken at V(i).  
Multiple imputation was performed for missing risk factor data in multivariable 
models. For each outcome, the multiple imputation included all predictors and the 
outcome. Missing values were imputed 5 times on the basis of the distribution of 
covariates by using a Markov-Chain Monte Carlo method assuming multivariable 
normality[22]. Missing values were imputed for multiple regression analyses for smoking 
status (2% of all person-visits data for analysis), CD4 cell count (<1% among HIV+), 
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HIV RNA (<1% among HIV+), HCV-infection (<1%), and HBV-infection (<1%). All 
analyses were done by using SAS 9.2 (SAS Institute, Cary, North Carolina, USA). 
Evaluation of hsCRP 
We cross-sectionally evaluated high sensitivity C-reactive protein (hsCRP) serum levels 
which were available from specimens drawn at routine visits during April to September 
2006, to assess associations of systemic inflammation with eGFR and proteinuria.  
Results 
Baseline Characteristics 
We analyzed eGFR changes among 2381 men.  At baseline, 1305 (54%) men were HIV-, 
917 (39%) were HIV+ and had initiated HAART, and 159 (7%) were HIV+ and 
HAART-naïve (Table 1). Among the 917 HAART users in our study, 60 were pre-
HAART ART-experienced. Table 1 shows differences in baseline characteristics in these 
patient groups with regard to hypertension, diabetes, HBV and HCV serostatus, and HIV 
clinical indicators.   
Risk Factors and Estimated GFR at Baseline 
Median baseline eGFR was 90 for HIV- men, 94 for HIV+ HAART-users, and 97 
for HIV+ HAART-naïve men (p=0.004 for HIV- vs. HIV+ HAART-users, p<0.001for 
HIV- vs. HIV+ HAART-naïve men). The proportion of men with baseline eGFR <60 was 
higher among HIV+ men receiving HAART (6%) than HIV- men (4%, p<0.001). 
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The prevalence of hypertension  (56%, 74%, and 88%, respectively; p<0.001 for 
trend) and of diabetes (9%, 11%, and 27%, respectively; p<0.001 for trend) increased 
while current smoking prevalence decreased (40%, 23% and 18%, respectively; p<0.001 
for trend) incrementally with lower baseline eGFR strata (≥90, 60-89 and <60). 
Association of Baseline Clinical Factors with Longitudinal Estimated GFR 
The median number of eGFR assessments performed per person during the 11-
year follow-up period was 19 for HIV- men, 19 for HIV+ HAART-users, and 7 for HIV+ 
HAART-naïve men. Median annual eGFR change was -0.5% overall, -0.8% for HIV+ 
men and -0.3% for HIV- men (p<0.001).   A 3% annual decline in eGFR represented 
approximately the lowest 15th percentile of the range of observed changes.  
For examining change in eGFR, men aged 50-59 and ≥60 years at baseline 
demonstrated similar trends, so were combined in the final multivariable model.  Factors 
independently associated with >3% annual eGFR decline included: HIV+ HAART+, age 
≥50, current smoking, a history of diabetes or hypertension, HCV infection, and MACS 
enrollment in 2001-03 (versus earlier, Table 2).  Men with baseline eGFR 60-89 
(compared to ≥90), Hispanic or other race (compared to White) and men with more 
eGFR measurements were less likely to have >3% annual eGFR decline. In this model, 
HBV infection, a history of AIDS, CD4 cell count, and detectable HIV RNA were not 
independently associated with eGFR decline. Among HAART-users, no specific 
antiretroviral drug use before baseline was independently associated with eGFR decline 
over the 11-year study period after adjusting for factors included in previous model. 
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Proteinuria Analysis  
 Proteinuria was detected in 1613 (7%) of 22,177 person-visit pairs: 243 (2%) of 
person-visit pairs from 64 HIV- men, 1337 (15%) of person-visit pairs from 260 HIV+ 
HAART-users, and 33 (6%) of person-visit-pairs from 9 HIV+ HAART-naive men.  
           Proteinuria was observed in 522 person-visit-pairs (36%) of the eGFR<60 group, 
694(7%) of the eGFR 60-90 group, and 397 (4%) of the eGFR>90 group (Figure). Within 
each eGFR stratum, proteinuria occurred more frequently among HIV+ HAART-users 
than HIV- men (all P<0.01).  Among 2059 men with at least three eGFR measurements 
and at least two urine UPCR measurements performed at two consecutive visits over the 
8-year period of follow-up, men with annual eGFR declines of  >3% more often 
exhibited proteinuria in at least one visit pair  (45%) than their counterparts (12%, OR= 
5.8, p< 0.001). 
 As shown in Table 3, factors independently associated with proteinuria were: 1) a 
baseline eGFR 60-90 or <60, versus >90; 2) >3% annual decline in eGFR; 3) HIV 
infection with HAART use; 4) age ≥ 50 vs. <40 at the visit prior to proteinuria detection 
(V(i-1)); 5) presence of any of the following at the V(i-1) visit: a history of diabetes or 
hypertension, current smoking, HCV infection, or  a CD4 ≤200 or 201-500 (vs. >500).   
Among HAART-users, use of didanosine, saquinavir or nelfinavir were additionally 
positively associated with proteinuria, while lamivudine use appeared protective. 
  The median eGFR decline was significantly (p <0.001) greater following 
confirmed proteinuria (-2.0% per year) than observed among those without proteinuria (-
0.70% per year).  The unadjusted odds ratios of having a subsequent annual eGFR 
decline of >3% among persons with proteinuria versus without proteinuria were 1.74 
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(95% CI:1.42-2.13, p<0.001), 2.09 (95% CI: 1.79-2.46, p<0.001), and 2.38 (95% 
CI:1.84-3.07, p<0.001) for men with GFR ≥90, 60-89, and <60 at V(i) , respectively. 
However, of the 1613 person-visit pairs with proteinuria, 39% had eGFR annual decline 
>3% before proteinuria was measured, while only 12% had prior eGFR annual decline
>3% of 20,564 person-visit pairs without proteinuria.   Table 4 illustrates that proteinuria
was significantly associated with subsequent eGFR decline (>3%) in the following year, 
after adjusting for other factors significantly associated with eGFR decline: a beginning 
eGFR >90, HIV infection, HAART receipt, age >40, cohort entered study in 2001-03, 
and a history of diabetes or hypertension.  Inclusion of CD4+ cell count in the 
multivariable model did not attenuate the association between proteinuria and subsequent 
eGFR decline (OR=1.77, 95% CI: 1.56-2.01).  In addition, among HAART-users, a 
detectable HIV RNA, cumulative use of tenofovir disoproxil fumarate, emtricitabine, 
ritonavir, atazanavir, any PI, or fluconazole were positively associated with a subsequent 
eGFR annual decline of >3% in separate models adjusting for proteinuria, HIV/HAART 
status, baseline eGFR level, age, race, cohort entry, and a history of diabetes or 
hypertension. The association of proteinuria with subsequent eGFR decline >3% tended 
to be stronger in men with eGFR<90 (Table 5).  
CRP Sub-Analysis 
 For the 12,608 UPCR person-visit-pairs at which CRP was measured, adding 
CRP (categorized as <1, 1-3, ≥3) to the final model revealed adjusted ORs for proteinuria 
of 1.70 (95% CI: 1.12-2.59) and 1.97 (95% CI: 1.28-3.02) for men with CRP levels of 1-
3 mg/L and ≥3 mg/L vs. <1 mg/L), respectively. Similarly, men with a CRP level ≥3 (vs. 
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<1) were more likely to have a subsequent eGFR decline of >3% in the next year after 
adjusting for proteinuria and other factors in the final model (OR=1.13 (95% CI: 1.02-
1.26).   
Discussion 
In this well-characterized, prospectively followed cohort of HIV-infected and 
uninfected men, we observed that declines in eGFR over an 11-year period were not 
clearly associated with HIV serostatus (though we studied few HIV+ persons not 
reveiving HAART) per se but were positively associated with HAART use in general. 
While HIV-infected HAART-recipients more often had low baseline kidney function 
(eGFR <60) than HIV-uninfected men, proteinuria was nearly 7 times more common in 
HAART-treated HIV-infected than HIV-uninfected men.  In addition proteinuria was 
more common among HIV-infected persons than were eGFR declines, and was 
concurrent with recent eGFR declines and highly predictive of subsequent eGFR 
declines. Proteinuria was also associated with historical exposure to didanosine, 
saquinavir or, and nelfinavir use, and positively correlated with systemic inflammation. 
Not unexpectedly, proteinuria was likewise more common in men with classic risk 
factors for kidney disease, such as hypertension, diabetes mellitus, and tobacco smoking. 
Longitudinal measurements of eGFR and concurrent serial assessments of proteinuria 
were available and, among HIV-infected persons on HAART, in analytic models that 
included adjustment for the presence of proteinuria, our observed associations of 
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cumulative use of TDF, emtricitabine, ritonavir, atazanavir, any PI, or fluconazole with 
eGFR declines in the following year, were noteworthy.  Associations between TDF use 
and GFR declines have been well-described in other cohorts[23-25]. Such declines are not 
always reversible[26, 27], may be cumulative, and may result in drug discontinuation. 
During the 11-year study period, HIV-infected participants often switched their HAART 
regimen over time (data not presented), which could have affected their subsequent eGFR 
levels. This may partly explain why no associations were seen between individual 
antiretroviral drugs used before baseline and the eGFR decline over the 11-year period. 
Recent data from other cohorts have indicated associations between cumulative 
atazanavir use and kidney function decline[28-32]. While our observed association between 
ritonavir use and eGFR decline was not unanticipated because of the drug’s inhibition of 
renal tubular creatinine secretion, eGFR declines may also have occurred because of 
ritonavir’s intended effects of increasing levels of atazanavir and of TDF, both drugs that 
can exhibit dose-dependent nephrotoxicity[33]. The association of emtricitabine use with 
eGFR decline likely reflects the fact that it was virtually always co-prescribed with TDF 
during the time period included in this study, and vice-versa, and rather than 
emtricitabine-induced adverse kidney effects. While our observed association between 
fluconazole use and eGFR decline was not expected, it may be related to the fact that 
fluconazole (both in the general HIV+ population as well as in our cohort) has been most 
often associated with having more advanced HIV infection (data not shown), higher 
plasma HIV viremia and lower CD4 count, all factors associated historically with worse 
kidney function among HIV+ persons.  The same principle may be have been operative 
in our finding of the association between historical exposure to didanosine, saquinavir or 
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nelfinavir with proteinuria; all of these were antiretroviral drugs used primarily in the 
early HAART era among patients who in general had more advanced HIV infection than 
more recent HAART-initiators. It is possible, though, that unmeasured indices of overall 
health may have influenced our observed associations between use of specific 
antiretroviral drugs with proteinuria and/or eGFR declines, despite having controlled for 
stage of HIV disease and the presence of important co-morbid diseases [34, 35]. 
The strong associations observed between proteinuria and HIV infection, HAART 
use, and more rapid declines in eGFR, were less pronounced but still apparent even 
among persons with baseline eGFRs in the normal range and support the hypothesis that 
proteinuria is concurrent with and predictive of kidney disease among HIV+ persons[36,
37]. We found that proteinuria was strongly predictive of subsequent eGFR decline over 
the next year, a finding that has been identified in HIV-uninfected populations[38-41]. 
Furthermore, the observed associations of known non-HIV causes of kidney disease 
(such as hypertension and diabetes) and proteinuria in our cohort are consonant with 
observations from other cohorts of HIV+ persons[1, 42-45], attesting to the sensitivity of 
proteinuria as a marker of incipient decline in GFR[11]. The extent to which and how HIV 
infection, specific antiretroviral drug use, and these other co-morbidities may interact to 
hasten the onset of proteinuria among HIV+ persons with other risk factors for kidney 
disease, is unclear. Nevertheless, the identification of proteinuria as a marker of eGFR 
decline may have implications for future research seeking to evaluate whether or not, 
among HIV-infected persons, specific therapeutic drug interventions for hypertension 
(such as ACE-inhibitors/ angiotensin receptor blockers) can ameliorate proteinuria-
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associated declines in kidney function, as has been observed in some subgroups of the 
proteinuric general population.  
  Our finding of a positive association between plasma CRP levels and proteinuria 
suggests that the latter is positively linked to the presence of systemic inflammation. The 
increased likelihood of proteinuria observed among persons in our cohort who had co-
existing chronic systemic illnesses associated with increased inflammation such as 
diabetes mellitus, as well as its positive association with tobacco smoking, support this 
hypothesis. Furthermore, our finding that, even in the presence of these co-morbid 
conditions, more advanced HIV infection remained independently associated with 
proteinuria and declines in kidney function, also supports an etiologic link between 
chronic systemic inflammation and proteinuria.  Other recent work from our group and 
others supports this[11, 46, 47]. The proportional contributions of HIV infection, specific 
antiretroviral drug use, and the presence of inciting co-morbid diseases toward the 
development of kidney disease (as evidenced by either proteinuria and eGFR decline) 
probably varies from individual to individual and likely has much to do with the severity 
and chronicity of the underlying systemic diseases as well as the success of medical 
management of each of the component illnesses.  
  In the overall cohort, we noted anticipated associations between eGFR declines, 
proteinuria and older age over the 11-year time period of observation represented in this 
report. Age-associated declines in eGFR have become more apparent in analyses of 
cohorts with longer periods of follow-up. Furthermore, the association between higher 
baseline eGFR (>90) with increased likelihood for subsequent declines in eGFR (Table 2) 
at first glance seems counterintuitive, but: 1) may reflect fact that persons with higher 
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GFRs have greater room for decline, particularly since, in general, we did not find 
differentially higher rates of non-HIV risks for kidney disease among persons with higher 
baseline eGFRs and; 2) may possibly be related to the phenomenon of hyperfiltration, 
which has been linked to more rapid subsequent kidney function decline among HIV+ 
persons[48, 49]. 
Limitations to this analysis exist. There may have been factors influencing eGFR 
decline that we did not or could not directly measure.  Also, determinations of 
relationships between specific antiretroviral use and eGFR declines or proteinuria can be 
complex. Most of our measurements were made while persons were already receiving 
HAART; most of these regimens did not constitute a given patient’s first exposure to 
antiretrovirals. Previously received antiretrovirals were not taken into account, and we 
did not evaluate pre-HAART eGFRs systematically.  This analysis reflects persons who 
entered care prior to 2003 and stayed in care for 11 years and may not be generalizable to 
persons who more newly entered care. Also, our report is subject to limitations that are 
inherent to analyses of any observational cohort. Another potential limitation is the 
inherent inaccuracy of eGFRs, even those based upon the most modern estimating 
equations, particularly among persons with higher true GFRs[50]. 
These observations support current clinical practices that include aggressive 
control of both HIV infection and any co-morbid conditions that are known to result in 
impaired renal function over time. Given the high and growing prevalence of traditional 
risk factors for chronic kidney disease among aging HAART-treated HIV+  persons, our 
findings support current recommendations advising that screening for kidney disease in 
HIV-infected persons should include routine assessments of both eGFR and proteinuria, 
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with the latter often providing the first indication that kidney dysfunction is present.   
Furthermore, our findings indicate that, among HIV+ persons with proteinuria, 
cumulative use of specific antiretrovirals, notably TDF and atazanavir may contribute to 
GFR decline. The extent to which these observations should inform antiretroviral 
selection, particularly among aging HIV+ persons with competing risks for kidney 
disease, and whether the current widespread use of newer antiretrovirals such tenofovir 
alafenamide that have fewer adverse renal effects or the use of NRTI-sparing  HAART 
will ameliorate the burden of HIV-related renal disease over time, requires further 
evaluation and will be the subject of future work from our group. 
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Table 1. Baseline characteristics of study population 
Characteristics HIV- HIV+ HAART+ HIV+ HAART- Overall 
Number of participants 1305 917 159 2381 
Age (years), N(%) 
   <40 256(20) 224(24) 49(31) 529(22) 
40-49 446(34) 400(44) 60(38) 906(38) 
50-59 419(32) 244(27) 46(29) 709(30) 
   >=60 184(14) 49(5) 4(3) 237(10) 
Race, N(%) 
   African American 263(20) 256(28) 65(41) 584(25) 
   Caucasian 916(70) 514(56) 72(45) 1502(63) 
   Hispanic 108(8) 132(14) 22(14) 262(11) 
   Other 18(1) 15(2) 0(0) 33(1) 
Estimated GFR (mL/min per 1.73 m2), N(%) 
   <60 46(4) 54(6) 1(1) 101(4) 
60-89 595(46) 342(37) 55(35) 992(42) 
   >=90 664(51) 521(57) 103(65) 1288(54) 
History of diabetes, N(%) 110(8) 132(14) 13(8) 255(11) 
History of hypertension, N(%) 873(67) 583(64) 86(54) 1542(65) 
Tobacco use, N(%) 
   Current 370(29) 312(34) 68(44) 750(32) 
   Former 565(44) 365(40) 48(31) 978(42) 
HCV-infection, N(%) 61(5) 92(10) 16(10) 169(7) 
HBV-infection, N(%) 18(1) 44(5) 11(7) 73(3) 
Cohort Entry Year, N(%) 
   Pre-2001 844(65) 479(52) 71(45) 1394(59) 
   2001-03 461(35) 438(48) 88(55) 987(41) 
Number of eGFR contributed during study 19(11-21) 19(11-21) 7(4-12) 18(10-21) 
CD4 count (cells/uL), median (IQR) 499(344-677) 534(403-733) 
Nadir CD4 count (cells/uL), median (IQR) 248(130-355) 441(329-591) 
HIV RNA (copies/mL), median (IQR) <50(<50-1460) 8468(512-29687) 
Undetectable HIV RNA, N(%) 552(60) 16(10) 
AIDS, N(%) 135(15) 2(1) 
% of ever used ARV; median (IQR) of cumulative years on 
ARV 
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Characteristics HIV- HIV+ HAART+ HIV+ HAART- Overall 
   Zidovudine (AZT) 79%;3.1(1.2-5.5) 
   Zalcitabine (DDC) 18%;0.9(0.3-1.8) 
   Didanosine (DDI) 44%;1.5(0.6-3.3) 
   Stavudine (D4T) 62%;3(1.4-5.2) 
   Lamivudine (3TC) 92%;3.9(1.9-6) 
   Abacavir (ABC) 39%;1.5(0.6-2.9) 
   Tenofovir disoproxil fumarate (TDF) 31%;0.9(0.5-1.4) 
   Emtricitabine (FTC) 2%;0.4(0.2-2.2) 
   Saquinavir (SQV) 25%;1.5(0.6-3.4) 
   Ritonavir (RTV) 43%;1.9(0.6-3.4) 
   Indinavir (IDV) 40%;2.5(0.9-4.8) 
   Nelfinavir (NFV) 36%;1.6(0.5-3.6) 
   Lopinavir (LPV) 22%;1.3(0.5-2.1) 
   Amprenavir (APV) 8%;1.5(0.6-3) 
   Atazanavir (ATZ) 3%;0.4(0.2-0.9) 
   Nevirapine (NVP) 32%;1.5(0.5-3.6) 
   Delavirdine (DLV) 3%;0.7(0.2-1.8) 
   Efavirenz (EFV) 47%;1.9(0.7-3.3) 
   Enfuvirtide (T-20) use 1%;0.4(0.3-1.8) 
   Raltegravir 0.4%;0.8(0.3-2) 
   Elvitegravir (including Stribild) 0%; 
   Dolutegravir (including Triumeq) 0%; 
   Fluconazole (FLU) 19%;0.9(0.3-2.8) 
   Protease inhibitors (PI) 73%;4.2(2.3-5.8) 
   Non-nucleoside reverse transcriptase inhibitor (NNRTI) 69%;2.2(1-3.9) 
   Nucleoside reverse transcriptase inhibitors (NRTI) 96%;5.9(3.3-8.5) 
   Integrase Inhibitors 0.4%;0.8(0.3-2) 
IQR: Interquartile range 
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Table 2.  Factors Associated with >3% Annual GFR Decline over an 11-year period 
among 2381 men 
Factors 
Unadjusted 
OR(95% CI) p-value
Adjusted 
OR(95% CI) p-value
HIV/HAART status at baseline 
   HIV- 1.00(ref) 1.00(ref) 
   HIV+, HAART- 2.20(1.37,3.53) 0.001 1.25(0.76,2.07) 0.377 
   HIV+, HAART+ 2.86(2.21,3.71) <0.001 2.91(2.21,3.83) <0.001 
Baseline eGFR(mL/min per 1.73m2) 
   >=90 1.00(ref) 1.00(ref) 
60-89 0.76(0.59,0.98) 0.034 0.76(0.57,1.02) 0.063 
   <60 1.75(1.06,2.88) 0.028 1.30(0.75,2.28) 0.351 
Baseline age (years) 
   <40 1.00(ref) 1.00(ref) 
40-49 1.09(0.78,1.51) 0.621 1.22(0.83,1.79) 0.314 
   >=50 1.15(0.83,1.58) 0.405 1.60(1.02,2.51) 0.039 
Race 
   White 1.00(ref) 1.00(ref) 
   Black 1.67(1.29,2.18) <0.001 1.13(0.80,1.59) 0.503 
   Hispanice/Other 0.77(0.50,1.18) 0.227 0.59(0.36,0.95) 0.030 
History of diabetes 2.29(1.66,3.15) <0.001 1.90(1.35,2.69) <0.001 
History of hypertension 1.60(1.22,2.09) <0.001 1.73(1.26,2.36) <0.001 
Smoking status 
   Never 1.00(ref) 1.00(ref) 
   Current 1.92(1.38,2.67) <0.001 1.46(1.02,2.09) 0.039 
   Former 1.35(0.97,1.89) 0.073 1.21(0.86,1.71) 0.274 
HCV-infection 2.53(1.75,3.66) <0.001 1.49(0.98,2.28) 0.064 
Number of eGFR contributed,per 1 count 0.93(0.91,0.94) <0.001 0.92(0.90,0.94) <0.001 
Cohort entry 2001-03 1.34(1.05,1.70) 0.018 1.48(1.03,2.14) 0.036 
21 
Table 3. Factors Associated with confirmed Proteinuria#*^
Factors 
Unadjusted 
OR(95% CI) p-value
Adjusted 
OR(95% CI) p-value
HIV/HAART status at baseline 
   HIV- 1.00(ref) 1.00(ref) 
   HIV+, HAART- 3.16(1.29,7.75) 0.012 3.28(1.29,8.34) 0.012 
   HIV+, HAART+ 8.93(6.19,12.87) <0.001 6.99(4.72,10.36) <0.001 
Baseline eGFR(mL/min per 1.73m2) 
   >=90 1.00(ref) 1.00(ref) 
60-89 1.27(0.94,1.72) 0.118 1.57(1.14,2.18) 0.006 
   <60 4.45(2.74,7.24) <0.001 4.15(2.52,6.84) <0.001 
eGFR decline >3% per year 4.75(3.69,6.11) <0.001 3.80(2.90,4.98) <0.001 
Age (years) 
   <40 1.00(ref) 1.00(ref) 
40-49 2.61(1.38,4.94) 0.003 1.39(0.71,2.71) 0.337 
   >=50 3.47(1.82,6.63) <0.001 2.04(1.01,4.08) 0.045 
History of diabetes 3.29(2.48,4.36) <0.001 2.35(1.75,3.17) <0.001 
History of hypertension 2.32(1.60,3.36) <0.001 1.92(1.31,2.79) <0.001 
Smoking status 
   Never 1.00(ref) 1.00(ref) 
   Current 2.04(1.39,2.99) <0.001 1.82(1.20,2.76) 0.005 
   Former 1.21(0.84,1.75) 0.295 1.19(0.82,1.72) 0.369 
HCV-infection 3.63(2.48,5.33) <0.001 2.13(1.36,3.32) <0.001 
CD4+ T-cell count(cells/µl) 
>500 1.00(ref) 1.00(ref) 
201-500 3.46(2.71,4.42) <0.001 1.26(0.97,1.62) 0.078 
   <=200 4.96(3.18,7.75) <0.001 1.86(1.13,3.08) 0.015 
Among HAART users 
   Use of didanosine* 1.09(1.04,1.15) <0.001 1.11(1.04,1.17) <0.001 
   Use of lamivudine* 0.98(0.94,1.02) 0.338 0.94(0.90,0.98) 0.004 
   Use of saquinavir* 1.12(1.03,1.20) 0.006 1.10(1.02,1.19) 0.013 
   Use of nelfinavir* 1.06(0.99,1.13) 0.102 1.09(1.03,1.15) 0.005 
#Among 2059 Men Who Contributed 22177 Person-Visit-pairs 
* Per year of drug use
^ Urine Protein-to-Creatinine >0.2 at two consecutive visits (no more than 1 year apart)
22 
Table 4. The Association between Proteinuria and Subsequent eGFR Annual Decline 
>3% in the following year#*^
Factors 
Unadjusted 
OR(95% CI) p-value
Adjusted 
OR(95% CI) p-value
Proteinuria 1.71(1.54,1.91) <0.001 1.80(1.58,2.05) <0.001 
HIV/HAART status at baseline 
   HIV- 1.00(ref) 1.00(ref) 
   HIV+, HAART- 0.85(0.72,1.01) 0.058 0.83(0.70,0.99) 0.039 
   HIV+, HAART+ 1.26(1.19,1.33) <0.001 1.20(1.11,1.29) <0.001 
eGFR(mL/min per 1.73m2)† 
   >=90 1.00(ref) 1.00(ref) 
60-89 0.69(0.64,0.74) <0.001 0.62(0.57,0.67) <0.001 
   <60 0.64(0.53,0.76) <0.001 0.43(0.36,0.51) <0.001 
Age (years) 
   <40 1.00(ref) 1.00(ref) 
40-49 1.17(1.06,1.31) 0.003 1.19(1.06,1.34) 0.004 
50-59 1.12(1.01,1.24) 0.035 1.26(1.11,1.43) <0.001 
   >=60 1.17(1.05,1.31) 0.005 1.52(1.31,1.75) <0.001 
Race 
   White 1.00(ref) 1.00(ref) 
   Black 1.19(1.11,1.27) <0.001 1.04(0.95,1.13) 0.447 
   Hispanic/Other 0.89(0.81,0.98) 0.013 0.80(0.71,0.90) <0.001 
Cohort entry 2001-03 1.10(1.04,1.17) <0.001 1.12(1.02,1.22) 0.013 
History of diabetes 1.22(1.14,1.31) <0.001 1.13(1.04,1.22) 0.003 
History of hypertension 1.15(1.07,1.23) <0.001 1.16(1.07,1.26) <0.001 
Among HAART users 
   Detectable HIV RNA (>=50 vs. <50 copies/ml) 0.99(0.99,1.00) 0.237 1.18(1.04,1.33) 0.011 
   Use of zidovudine* 1.02(1.00,1.04) 0.011 0.99(0.98,1.00) 0.021 
   Use of tenofovir* 1.04(1.02,1.06) <0.001 1.03(1.01,1.04) 0.002 
   Use of emtricitabine* 1.01(1.00,1.02) 0.172 1.05(1.03,1.07) <0.001 
   Use of ritonavir* 1.02(1.00,1.04) 0.110 1.01(1.00,1.02) 0.084 
   Use of atazanavir* 1.03(1.00,1.05) 0.018 1.03(1.01,1.06) 0.007 
   Use of fluconazole* 1.03(0.99,1.07) 0.130 1.04(1.00,1.08) 0.072 
   Use of Protease Inhibitors* 1.01(1.00,1.02) 0.066 1.01(1.00,1.02) 0.070 
#Among 1969 men who contributed 20331 Person-Visit-pairs with Urine Protein-to-
Creatinine measured and 3 eGFR measurements in the following year 
23 
* Per year of drug use; each drug was examined in separate model adjusted for other
factors listed in the Table.
^ Urine Protein-to-Creatinine >0.2
†At the visit when proteinuria was confirmed
24 
Table 5. Association of proteinuria and subsequent eGFR decline>3% by eGFR level 
Prevalence of subsequent 
eGFR decline >3%  
Adjusted* OR 
(95% CI) of 
subsequent eGFR 
decline >3% for 
proteinuria 
P-value for the
interaction of
eGFR category and
proteinuria
Without 
Proteinuria 
With 
Proteinuria 
eGFR<60 24% 43% 2.06 (1.43-2.97) 0.063 
eGFR 60-90 31% 48% 1.88 (1.58-2.24) 0.175 
eGFR >=90 40% 54% 1.53(1.22-1.93) (reference) 
*Adjusted for HIV/HAART status, age, race, cohort status, history of diabetes, and
history of hypertension.
CI: confidence interval
25 
 
 
 
 
 
     
 
  Figure: Relationship between Baseline GFR and Likelihood of Demonstrating 
Proteinuria During Follow-up, by HIV Serostatus and HAART Use Status 
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